ARVINAS INC. news, videos and press releases
For more news please use our advanced search feature.
ARVINAS INC. - More news...
ARVINAS INC. - More news...
- Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation
- Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
- Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
- Arvinas to Participate in Upcoming Investor Conferences
- Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
- Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
- Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
- Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
- Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference
- Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium
- Arvinas to Participate in Upcoming Investor Conferences
- Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day
- Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024
- Arvinas to Participate in Upcoming Investor Conferences
- Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
- Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
- Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
- Arvinas to Participate in Upcoming Investor Conferences
- Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
- Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
- Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
- Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Arvinas to Present at Upcoming Investor Conferences
- Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
- Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
- Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
- Arvinas to Participate in Upcoming Investor Conferences
- Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
